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Abstract
Chromatin remodeling is a key mechanism in adipocyte differentiation. However, it is unknown whether dietary polyphenols are epigenetic effectors for
adiposity control. Ellagic acid (EA) is a naturally occurring polyphenol in numerous fruits and vegetables. Recently, EA-containing foods have been reported to
reduce adiposity. In the present study, we sought to determine whether EA inhibits adipogenesis by modifying chromatin remodeling in human adipogenic stem
cells (hASCs). qPCR microarray of chromatin modification enzymes revealed that 10 μmol/L of EA significantly inhibits histone deacetylase (HDAC)9 downregulation. In addition, EA was associated with up-regulation of HDAC activity and a marked reduction of histone acetylation levels. However, chemical inhibition
of HDAC activity or depletion of HDAC9 by siRNA were not sufficient to reverse the antiadipogenic effects of EA. Intriguingly, EA treatment was also associated
with reduced histone 3 arginine 17 methylation levels (H3R17me2), implying the inhibitory role of EA in coactivator-associated arginine methyltransferase 1
(CARM)1 activity during adipogenesis. Boosting CARM1 activity by delivering cell-penetrating peptides of CARM1 not only recovered H3R17me2 but also
restored adipogenesis evidenced by H3 acetylation at lysine 9, HDAC9 down-regulation, PPARγ expression and triglyceride accumulation. Taken together, our
data suggest that reduced CARM1 activity by EA results in a decrease of H3R17me2 levels, which may interrupt consecutive histone remodeling steps for
adipocyte differentiation including histone acetylation and HDAC9 dissociation from chromatin. Our work provides the mechanistic insights into how EA, a
polyphenol ubiquitously found in fruits and vegetables, attenuates human adipocyte differentiation by altering chromatin remodeling.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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1. Introduction
Epigenetic modification refers to the inheritable changes of gene
expression in the absence of a change in the DNA sequence itself.
Epigenetic modification comprises DNA methylation in CpG islands,
covalent modification of histone tails and noncoding microRNAmediated gene silencing [1–6]. In particular, histone modification is a
key mechanism in the switching on and off of genes for differentiation; N-terminal tails of H3 and H4 interact with the negatively
charged DNA backbone in unmodified states. Histone-modifying
enzymes target specific amino acids of histones, producing changes in
acetylation, methylation, phosphorylation or ubiquitination status.
Modifications of these histone codes alter chromatin conformation,
which subsequently induce dissociation of transcriptional (co)
repressors as well as recruitment of transcriptional (co)activators
[7–10]. In general, histone acetylation on lysine residues decreases
the chromatin compactness, increases accessibility to genes and
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thereby induces transcriptional activation. Several transcriptional
coactivators possess histone acetyltransferase (HAT) activity to
transfer acetyl groups to lysine residues in histones, promoting
conformational change in euchromatin structure [11–14]. In contrast,
transcriptional co-repressors often possess Histone deacetylase
(HDAC) activity to remove acetyl moieties from histone tails, leading
to less accessible heterochromatin conformation [15,16]. Regulation
of transcription by histone methylation is more complex than by
histone acetylation. Histone methylation can be correlated with
either gene activation or repression depending on histone residues
(lysine or arginine), specific genetic loci or distinctive methylation
pattern (e.g., asymmetric or symmetric) [17–21].
A growing body of literature has revealed that epigenetic
regulation is a key mechanism for adipocyte differentiation. Although
considered controversial, an increase in global histone acetylation is
preceded by adipocyte differentiation as the consequence of decreased HDAC activity [22]. More specifically, H3 acetylation at lysine
9 (H3K9Ac) and H3 methylation at lysine 4 (H3K4me2) have been
implicated for positive regulation of adipocyte differentiation [23].
The obligatory suppression of Wnt signaling is also regulated by
chromatin modification via H3 lysine 27 (H3K27Ac vs. H3K27me3)
[24]. Several histone modification enzymes, that is, protein arginine
methyltransferase 4 [also known as coactivator-associated arginine
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methyltransferase 1 (CARM1)] [25], PRMT5 [26], histone methyltransferase G9a [27] and HDAC9 [28], have been identified as either
positive or negative regulators for adipocyte differentiation. Moreover, recent advances in chromatin immunoprecipitation methodology have revealed that activation of transcriptional cascade networks
during early adipogenesis coincides with the regulation of histone
modification of key transcription factors such as peroxisome
proliferator-activated receptor gamma (PPARγ) [25]. These studies
have clearly demonstrated that chromatin remodeling dictates
adipocyte differentiation.
However, less information is available whether environmental
effectors are able to reprogram epigenetic codes for adipocyte
differentiation. Interestingly, accumulating evidence suggests that our
daily diet is an important epigenetic determinant regulating obesity.
Exposure to an High fat (HF)-diet early in life can alter chromatin
structure, leading to an increased risk of obesity in adulthood [29–31].
Conversely, consumption of fruits and vegetables (FV) is inversely
associated with obesity [32]. FV-mediated weight loss is due to
decreased energy-density/increased satiety by high-fiber intake, and
enhanced energy metabolism probably by a variety of phytochemicals
exists in FV [33]. However, it is largely unknown whether epigenetic
regulation could be a viable mechanism to explain the reduced adiposity
by FV consumption. It is plausible to hypothesize that FV contain
principle phytochemicals that can modulate the activity of chromatinmodifying enzymes, thereby reducing adiposity. Recently, our group
has reported that supplementation of muscadine grape polyphenols
(MGP) decreased visceral obesity and obesity-mediated metabolic
complications compared to muscadine wine polyphenols (MWP) [34].
In that study, we noticed that ellagic acid (EA) was the major
compositional difference between MGP and MWP (18.2 vs. 1.1 mg/g
extract, respectively) because EA was removed during the typical winemaking procedures by filtration. It led us to hypothesize that EA
regulates adiposity probably by altering epigenetic marks for adipogenesis. Here, we present evidence that EA, a polyphenol commonly
found in many FV, attenuates adipocyte differentiation by modulating
histone arginine methylation and subsequent histone acetylation levels.

2. Materials and methods
2.1. Materials
All cell culture dishes were purchased from Fisher Scientific. Fetal bovine serum was
purchased from Cellgro. Rosiglitazone (BRL49653) was purchased from Cayman
Chemical. All other chemicals and reagents were purchased from Sigma Chemical Co., unless
otherwise stated.

2.2. Preparation of human adipogenic stem cells (hASCs) and adipogenic differentiation
Abdominal adipose tissue was obtained from females with a body mass index of
~30 during liposuction or abdominal plastic surgeries. Isolation of hASCs and
differentiation of adipocytes were conducted as described by Skurk et al. [35]. All
protocols and procedures were approved by the Institutional Review Board (#6932011) at the University of Florida. After removing initial monocytic cells (selective
adherence to plastic), the released stromal vascular (SV) fractions were passaged down no
more than three times. These adipogenic stem cell rich SV fractions are regarded as hASCs
without further purification procedures [36]. A pool of hASCs from three or four different
human subjects was used for each experiment to avoid individual variation. Conditions for
hASCs proliferation and differentiation were described previously [37]. EA (E2250, Sigma)
stock was prepared in dimethyl sulfoxide (DMSO); aliquots of stock (10 mmol/L) were
kept at −20°C and freshly diluted at the time of addition to hASCs. For the treatment of EA,
confluent cultures of hASCs (d0 preadipocyte) were induced to differentiate in the
presence of 10 μmol/L of EA (final in 0.1% DMSO) in human adipocyte medium AM-1
(ZenBio) plus differentiation cocktail for 3 days (d1-d3 adipocyte). Upon 4 days of
differentiation (d4), medium was changed with AM-1 plus fresh EA (10 μmol/L) without
differentiation cocktail. Since then, medium was replenished with fresh addition of EA. The
cultures of human adipocytes were harvested on d4 or d7 based upon experimental design.
All EA treatments were paralleled with vehicle controls (0.1% DMSO). The presence of
intracellular lipid accumulation was visualized by oil red-O (ORO) staining.
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2.3. qPCR and microarray analysis
Gene-specific primers for real-time PCR (qPCR) were obtained from Integrated DNA
Technologies (Chicago, IL, USA). Total mRNA of hASCs was isolated using Trizol reagent
(Invitrogen). To remove genomic DNA contamination, mRNA was treated with DNase
(Mediatech); 2 μg of mRNA was converted into cDNA in a total volume of 20 μL (iScript cDNA
synthesis kit, Bio-Rad). Gene expression was determined by qPCR (CFX96, Bio-Rad), and
relative gene expression was normalized by 36B4. The complete gene lists can be found in
Supplemental Table 1. For PCR microarray analysis, RT2 profiler PCR array for human
epigenetic chromatin modification enzymes (QIAGEN, PAHS-085Z) was used according to
the manufacture's protocol. For each group, pools of equal amounts of total mRNA provided
from four different human subjects were used. The results were analyzed using software
provided by QIAGEN (http://www.sabiosciences.com/pcrarray data analysis.php#Excel).
2.4. Western blot analysis
To prepare total cell lysates, monolayers of differentiated cultures of human
adipocytes were harvested with ice-cold Radioimmunoprecipitation assay buffer (RIPA)
buffer (Thermo Scientific) with protease and phosphatase inhibitors (Sigma). For nuclear
extract preparation, NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific)
was used according to the manufacturer's protocol. Proteins were fractionated onto 4–15%
precasted Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDA-PAGE)
(Biorad), transferred to PVDF membranes with a semidry transfer unit (Hoefer TE77X)
and incubated with the relevant antibodies. Chemiluminescence from Enhanced
chemiluminescence (ECL) solution (Western Lightning) was detected with FluorChem
E (Cell Biosciences) imaging system. Polyclonal or monoclonal antibodies targeting to βactin (4967), H3K9Ac (AcH3, 9649), HDAC1 (5356), HDAC2 (5113), HDAC3 (3949),
HDAC4 (7628), HDAC5 (2082), HDAC6 (7558), AcH4 (2594), H3K27Ac (4353), H4 (2935),
lamin A/C (4777) and CARM1 (3379) were purchased from Cell Signaling Technology.
Antibodies to HDAC9 (ab 59718) and histone H3 (ab1791) were purchased from Abcam.
PPARγ (sc-7273) and FABP (aP2, sc-271529) were purchased from Santa Cruz Biotechnology.
The polyclonal antibody for detecting H3R17me2 (NB21-1132) was purchased from Novus
Biotechnology.
2.5. HDAC enzyme activity assays
Total cellular histone deacetylase enzymatic activity was measured using a
commercial HDAC assay kit (Upstate Biotechnology) according to the manufacturer's
protocol. Briefly, 30 μg of nuclear lysate were incubated with fluorescent substrate in
HDAC assay buffer for 45 min at 30°C. An activator solution was added to release the
fluorophore from the deacetylated substrates, and fluorescence was measured in a
multichannel fluorometer (Synergy H1, Biotech).
2.6. Depletion of HDAC9 using siRNA
For silencing HDAC9, hASCs were seeded at confluent density and allowed to
attach for 24 h in a proliferation medium. Culture of hASCs were transfected with either
200 nmol/L of human HDAC9 ON-TARGET plus SMART pool siRNA (Thermo Scientific)
or 200-nmol/L nontargeting control siRNA (Thermo Scientific) using DharmaFECT1
transfection reagent according to the manufacturer's protocol. The transfection
efficiency was determined by Cy3-tagged siGLO (Thermo Scientific). After 48 h of
transfection, hASCs were stimulated for differentiation for 3 days in the presence and
absence of EA (Fig. 3A).
2.7. Immunocytochemistry of H3R17me2 and HDAC9
hASCs were cultured onto coverslips and immunostained as described previously
[38]. Briefly, cells were fixed with 3.7% paraformaldehyde for 20 min. After quenching
paraformaldehyde with glycine, coverslips were permeabilized with ice-cold Triton X-100
(0.1%) and blocked with 1.25-mg/ml normal goat serum for 1 h. The coverslips were incubated
overnight with 1:100 dilution of the antibodies of H3R17me2 (ab8284) and HDAC9 (ab18970)
antibody (Abcam) at 4°C, followed by incubation for 1 h with a 1:300 dilution of rhodamine
red-conjugated goat antirabbit IgG (Jackson Immunoresearch). Fluorescent images were
captured using a digital inverted fluorescence EVOS microscope (AMG Inc.). 4′,6-diamidino-2phenylindole (DAPI) staining was used for counter staining of the nucleus.
2.8. Cell permeable peptide-CARM1 (CPP-CARM1)
Purified CPP-CARM1 was a generous gift from Dr. Dong Ryul Lee at the CHA
University in South Korea [39]. CPP-CARM1 (2 μg/ml) was delivered to hASCs 24 h
prior to adipogenic stimulation with or without EA. This allows sufficient time for CPPCARM1 to translocate into the nucleus before hASCs are exposed to EA. Every 2 days,
fresh CPP-CARM1 was added during routine media changes.
2.9. Statistics
All data are presented as the mean±S.E.M. The data were statistically analyzed
using Student's t-test or one-way analysis of variance (ANOVA) with Tukey's multiple
comparison tests. All analyses were performed with GraphPad Prism 5 (Version 5.04).
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3. Results
3.1. EA alters HDAC9 expression and HDAC activity during
adipocyte differentiation
Recently, we and others have reported that supplementation with
EA-containing foods is associated with reduced adiposity [34,40,41].
To gain an insight into whether EA regulates epigenetic factors of
adipogenesis, we performed qPCR microarrays for chromatin modification enzymes using hASCs. Among the 84 genes that regulate
chromatin accessibility to genomic DNA or histones (by altering the
status of acetylation, methylation, phosphorylation or ubiquitination), 10 genes were up-regulated (Ntwofold) by EA treatment
without any specific genes being down-regulated significantly
(btwofold) (Fig. 1A, also see Supplemental Table 2). In particular,
HDAC9 gene expression levels were ~twentyfold higher than that of
vehicle control. To validate the array results, HDAC gene expressions
were measured using individual gene-specific primers. As we expected,
no difference was found in Class I (HDAC 1, 2, 3, 4 and 8) or Class III
HDAC genes between EA-treated and control human adipocyte samples.
In parallel to results from the qPCR array, HDAC9 gene expression was
specifically higher in EA-treated adipocytes compared to vehicle
controls among the Class II HDAC genes (HDAC 5, 7, 9 and 10).
Interestingly, for HDAC11, a Class IV HDAC enzyme, mRNA levels were
also significantly higher than control (Fig. 1B). HDAC9 protein
expression was higher in EA-treated nuclear fraction, while other
HDAC protein levels were similar between the two groups (Fig. 1C).
Next, we examined whether EA also alters HDAC activity and
histone acetylation levels. There was a b50% reduction of global HDAC
activity during the early differentiation period (4 days after exposure
to differentiation stimuli), which was almost completely dampened
in cultures grown with EA (Fig. 2A). In the presence of 100 nmol/L
trichostatin A (TSA), a pan-HDAC inhibitor, there was an additional
decrease of HDAC activity in the nuclear extract of differentiated
cultures; only ~10% of HDAC activity remained in comparison to
undifferentiated hASCs (Fig. 2B, the second bar). In contrast, EAtreated nuclear extracts still possessed 50% of HDAC activity in the
presence of TSA (Fig. 2B, the last bar). Consistent with the literature
[22,24], differentiation of hASCs significantly increased acetylation
levels of H3K9Ac, H3K27Ac as well as AcH4 (Fig. 2C, left panel).
Intriguingly, differentiation of hASCs with EA remarkably decreased
histone acetylation levels (Fig. 2C, right panel). To answer the
question of whether the inhibition of HDAC activity could reverse
the inhibitory effects of EA on adipogenesis, TSA was added to the
hASCs along with EA. Consistent with results from Chatterjee et al.
[28], the addition of TSA during the adipocyte differentiation
procedures did not inhibit adipogenesis (Fig. 2D, upper panel).

Similarly, addition of TSA to EA-treated cultures during adipocyte
differentiation failed to restore both adipocyte morphology (Fig. 2D)
and PPARγ expression (Fig. 2E). Notably, HDAC9 gene expression
was even higher with TSA treatment, suggesting that HDAC9
expression is not regulated by TSA-sensitive HDAC activity
(Fig. 2E). These results collectively demonstrated that (a) EA
inhibited down-regulation of HDAC activity, presumably the TSAinsensitive portion; and (b) chemical inhibition of HDAC activity by
TSA was unable to reverse EA-mediated HDAC9 expression as well as
inhibition of adipogenesis.
3.2. Silencing of HDAC9 is not sufficient to reverse the reduction of
adipocyte differentiation by EA
It has been shown that HDAC9 is a transcriptional co-repressor of
adipogenesis by preventing the activation of C/EBPα [28]. Our next
question was whether the knockdown of HDAC9 could reverse the
anti-adipogenic effects of EA. To address this question, we used siRNA
to deplete HDAC9. Transfection efficiency of hASCs was N90%
estimated by Cy3-tagged nontargeting siGLO (data not shown). To
knockdown HDAC9, 200 nmol/L of siCont (nontargeting) or siHDAC9
were transfected with hASCs for 48 h followed by adipogenic
differentiation for 72 h (Fig. 3A). Transfection of siHDAC9 attenuated
HDAC9 gene expression approximately ~70% compared to siCont
(Fig. 3B), which remained constant throughout the experiment (data
not shown). Reduction of HDAC9 protein levels in the nucleus by
siHDAC9 was comparable to siCont transfected cells without EA
(Fig. 3C). Surprisingly, a substantial decrease of HDAC9 by siHDAC9
had minimal impact on EA-mediated suppression of adipogenic gene
expression, C/EBPα and PPARγ or on H3K9 acetylation (Fig. 3B, C).
These data showed that the reduction of HDAC9 was unable to reverse
the inhibition of adipogenesis by EA. In addition, this implicates
that additional regulatory factor(s) might be involved in the
suppression of adipocyte differentiation by EA other than HDAC9
regulation per se.
3.3. Inhibition of CARM1 by EA plays a key role in suppressing adipogenesis
Recently, EA has been identified as a novel inhibitor for CARM1
[42], whose activity is required for asymmetric transfer of two methyl
groups to the H3R17me2 (Fig. 4A). Consistently, immunostaining of
differentiated human adipocyte cultures (heterogeneous culture
containing ~50% adipocytes) with an H3R17me2 antibody showed
that CARM1 activity is restricted to lipid-laden adipocytes but not in
undifferentiated hASCs (Fig. 4B). To further determine whether
inhibition of CARM1 activity by EA would be a key mechanism to
block hASCs differentiation, we examined the H3R17me2 levels

Fig. 1. EA alters HDAC9 expression during adipocyte differentiation. Cultures of hASCs were induced to differentiation in the presence of 10-μmol/L EA or DMSO (vehicle) for 7 days. (A) Microarray
analysis of human chromatin modification genes (84 genes) by qPCR from the hASCs treated with either 10-μmol/L EA or vehicle for 7 days during differentiation. Pooled mRNA from four different
human subjects was used for analysis. Broken lines indicate twofold expression of differences between treatments. (B) Gene expression levels of Class I, II and IV of HDAC and sirt1 and 2 (Class III) by
qPCR. (C) Protein expression levels of HDAC 1, 2, 3, 4, 6 and 9 in nuclear extract. H3 and lamin A/C were used for loading control. *Pb0.05, *** Pb0.001 by Student's t test.
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Fig. 2. EA alters HDAC activity during adipocyte differentiation. (A) Nuclear HDAC enzyme activity in undifferentiated (Diff −) and differentiated (Diff +) adipocytes in the presence or
absence of EA for 4 days. (B) HDAC activity with or without pan-HDAC inhibitor TSA (100 nmol/L). (C) Western blot analysis for detecting H3K9Ac and H3K27Ac and AcH4. H3, H4 and
lamin A/C were used for loading control and aP2 used as an adipocyte marker. (D) Phase contrast images of hASCs differentiated with either EA or TSA only, or cotreatment of TSA+EA
for 7 days. (E) PPARγ and HDAC9 gene expression grown in the presence or absence of TSA and EA. All values are presented as the mean±S.E.M. Means without a common letter differ
(aNbNc, Pb0.05) by one-way ANOVA.

during differentiation with or without EA incubation. Supporting the
important role of CARM1 activity in adipocyte differentiation, EA
treatment significantly reduced H3R17me2 levels compared to
vehicle control from the nuclear extract fraction used in Fig. 1C
(Fig. 4C). However, there was no significant difference in mRNA or
protein levels of CARM1 (Fig. 4C, D), suggesting that EA inhibits
enzyme activity of CARM1 rather than by transcriptional or translational
modification of CARM1.
If the inhibition of CARM1 activity by EA is the major mechanism to
block the adipogenesis, the replenishment of CARM1 activity can rescue

adipocyte differentiation. To test this concept, 2 μg/ml of recombinant
cell-penetrating peptide-CARM1 (CPP-CARM1) [39] were added to
hASCs throughout the adipogenic differentiation with 10-μmol/L EA.
Although adipocyte morphology was not completely restored, addition
of CPP-CARM1 substantially increased triglyceride (TG) accumulation
compared to EA-only treatment assessed by ORO staining (Fig. 5A).
Accordingly, costimulation of CPP-CARM1 with EA significantly
increased PPARγ gene and protein expression compared to EA
treatment alone (Fig. 5B, C). The restoration of CARM1 activity by
adding CPP-CARM1 also increased H3R17me2 and H3K9 acetylation

Fig. 3. Depletion of HDAC9 in hASCs has minimal impact on EA-mediated inhibition of adipogenesis. (A) Experimental scheme for depletion of HDAC9 before adipogenic differentiation
with or without EA. hASCs were transfected with siCont or siHDAC9 at 48 h before differentiation. Differentiated cultures were kept for 3 days before harvest of mRNA and protein
after differentiation. (B) Relative gene expression of HDAC9, C/EBPα and PPARγ by qPCR analysis. (C) Protein levels of HDAC9, AcH3, H3R17me2, aP2, lamin A/C and total H3 in siCont
or siHDAC9 transfected cells. All values are presented as the mean±S.E.M. *Pb0.05 by one-way ANOVA.
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Fig. 4. EA inhibits H3R17me2 without affecting CARM1 expression levels. (A) EA inhibits CARM1-mediated methylation of H3 arginine 17 in adipocytes. (B) Immunolocalization of
H3R17me2 (red) and DAPI (blue). Differentiated hASCs were immunostained with H3R17me2 antibody, and the nuclei were counterstained by DAPI. Phase contrast image (40X) was
overlapped to distinguish lipid loaded adipocytes versus undifferentiated cells. (C) Inhibition of H3R17me2 by EA without changes of CARM1 protein levels. Lamin A/C was used for
loading control and PPARγ used as an adipocyte marker. (D) CARM1 gene expression measured by qPCR. Data are presented as the mean±S.E.M. ns=not significant by Student's t test.

levels (Fig. 5C). Moreover, immunostaining of HDAC9 revealed that
the addition of CPP-CARM1 reduced EA-mediated retention of
HDAC9 in nucleus (Fig. 5D). Taken together, these data strongly
suggest that inhibition of H3R17me2 by EA is the key step to repress
the subsequent H3K9 acetylation, HDAC9 dissociation from chromatin and PPARγ activation.
4. Discussion
White adipose tissue is not only a storage organ for surplus energy
but is also an active endocrine tissue critical in energy and glucose
homeostasis [43–45]. The metabolic and endocrine function of
adipocytes correlates to the dynamics of adipocytes, that is, adipocyte
size and numbers [46]. Plasticity of the adipocytes seems to be
dictated by chromatin remodeling and transcriptional networks in
response to environmental effectors such as diet [47,48]. Currently,
little is known about the regulatory role of dietary polyphenols on
epigenetic remodeling in adipocytes. The goal of this study was to
identify potential links between dietary EA and epigenetic regulation
of adipogenesis. We demonstrated that EA, a ubiquitous polyphenol
in FV, inhibits adipocyte differentiation through CARM1-mediated
epigenetic modification. Based upon our results, we propose the
following working model (Fig. 6): uncommitted hASCs are associated
with high levels of HDAC9 that repress transcriptional activation of
adipogenic genes [28]. Upon adipogenic stimuli, CARM1 enzyme
facilitates the transfer of two methyl moieties to H3R17, which is
accompanied by a subsequent H3K9 acetylation and HDAC9 dissociation. In the presence of EA, the inhibited CARM1 activity by EA
results in the suppression of H3R17 methylation, which in turn
abolishes H3K9 acetylation and HDAC9 dissociation, and ultimately
represses adipogenesis.
Extensive research from several groups has identified that
histone-modifying enzymes play pivotal roles in adipocyte development: (a) deletion of histone methyl-transferase enhancer of zeste
homolog (Ezh2) abolished trimethylation on H3K27 of Wnt promoter
region, resulting in constitutive activation of Wnt signaling and
transcriptional inhibition of adipogenesis [24]; (b) silencing of PRMT5
repressed adipogenic gene expression, which was reversed by PRMT5
overexpression [26]; (c) histone methyltransferase G9a seemed to
play dual roles for turning on or off adipogenic signaling based on its
methylation sites by serving as a coactivator or co-repressor [49];
(d) Class II HDACs have been reported to control PPARγ signaling [50].
Among the Class II HDACs, HDAC9 has been identified as a unique

transcriptional co-repressor on C/EBPα promoter [28]; and (e) mice
born with the deletion of CARM1 lacked in fat pad development [51,52]
identifying the adipose-specific role of CARM1 as a coactivator for
PPARγ [25].
Despite accumulated evidence demonstrating the critical roles of
histone-modifying enzymes in adipogenesis, few studies have identified the specific effectors that directly alter histone reprogramming by
modulating histone modifying enzymes. In this study, we have
identified that EA alters at least three distinctive epigenetic factors
during adipogenesis of hASCs.
The first modification that we immediately noticed was the
abnormally high expression of HDAC9 via qPCR microarray of
histone-modifying enzymes (Fig. 1). However, an increase of HDAC9
levels did not seem to be a major cause for EA-mediated inhibitory effects
on adipogenesis due to the following reasons: (a) depletion of
HDAC9 up to ~70% had minimal effects on adipogenesis (Fig. 3)
suggesting the existence of anti-adipogenic regulatory factor(s) that
could occur ahead of HDAC9 regulation; and (b) if HDAC9-mediated
HDAC activity is the key mechanism to inhibit adipogenesis,
inhibition of HDAC9 activity by TSA (it has been shown that
HDAC9 activity is inhibited by TSA treatment [22]) should restore
adipogenic potential, which was not the case in our experiment
(Fig. 2D, E). These results are consistent with the conclusion from
Chatterjee et al. [28] demonstrating that HDAC9 represses the
adipogenic transcription factor in a deacetylase-independent mechanism. Based on our observations, EA seems to cause an earlier
modification before the HDAC9 dissociation step (HDAC9 downregulation is necessary but not sufficient to initiate adipogenesis).
The second modification that we noticed was decreased histone
acetylation levels and increased HDAC activity by EA (Fig. 2A, C). The
role of histone acetylation on adipogenesis seems to be inconsistent;
inhibition of HDAC activity by TSA inhibited adipogenesis in 3 T3-L1
cells [22], while it failed to inhibit adipogenesis in primary adipogenic
precursor cells in mice and humans [28]. One thing we confirmed was
that TSA-sensitive HDAC activity is not required for adipogenesis at
least in hASCs ([28], our data Fig. 2D, E). Thus, the down-regulation of
the TSA-insensitive portion of HDAC activity might be critical to
initiate adipogenic differentiation. This is based upon our data
showing that EA treatment during adipogenesis almost completely
blocked the down-regulation of HDAC activity (Fig. 2A); and that
cotreatment of EA and TSA decreased the only TSA-sensitive HDAC
activity without promoting adipogenesis (Fig. 2B). Conversely, it
indicates that the down-regulation of TSA-insensitive HDAC activity
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Fig. 5. Rescue of CARM1 activity by delivering CPP-CARM1 reverses EA-mediated adipogenesis of hASCs in part.CPP-CARM1 was delivered to hASCs at 24 h prior to adipogenic
differentiation then differentiation was induced in the presence or absence of EA for 7 days. (A) TG accumulation was visualized by ORO staining. Black boxes show magnified images.
(B) PPARγ gene expression by qPCR. (C) Protein levels of H3R17me2, H3K9Ac, H3 and PPARγ by Western blot analysis. (D) Immunostaining of HDAC9 was merged with DAPI staining
to show decreased HDAC9 levels in CPP-CARM1-added cultures. Data are presented as the mean±S.E.M., **Pb0.001 by Student's t test.

may be required for adipogenesis. Intriguingly, we did not find any
evidence that EA directly alters HDAC or HAT activity (data not
shown). This is also consistent with the report from Selvi et al.
[42]. Although the mechanistic link between EA treatment and
“HDAC/HAT activity and histone acetylation status” is uncertain, our
results suggest that EA may inhibit earlier signals that could lead to
global histone acetylation for facilitation of adipogenesis.
The third and the most fundamental epigenetic modification that
we have identified was the attenuation of H3R17me2 levels by EA,
due to reduced CARM1 activity (Fig. 4). Yadav et al. have established
the role of CARM1 as a PPARγ coactivator in adipose tissue [25], and
Selvi et al. have reported the general effects of EA on CARM1 enzyme
[42]. However, our work is the first to report that EA inhibits
asymmetric dimethylation of H3R17 during adipogenic differentiation in hASCs by linking CARM1 activity to the anti-adipogenic effects
of EA. It was unexpected to find that HDAC9 depletion could not
restore the H3R17me2 in the presence of EA (Fig. 3). This implies that
the modification of CARM1 activity may precede the dissociation of
transcriptional repressor HDAC9. It is important to note that regaining
CARM1 activity by adding CPP-CARM1 recovered HDAC9 dissociation

from the nucleus, histone acetylation, adipogenic gene expression
and TG accumulation (Fig. 4). These data clearly demonstrated that
the modulation of CARM1 by EA is a key mechanism to inhibit
successive epigenetic modification for adipocyte differentiation, that
is, releasing transcriptional (co)repressors. The exact mechanistic
regulations collaboratively control methylation on H3R17, releasing
HDAC9 from chromatin (probably from PPAR response elements
peroxisome proliferator-activated receptor response element
(PPRE)), and acetylation of histone are currently unknown. A recent
work by Wu et al. demonstrated that arginine methylation on H3R17
and H3R26 by CARM1 is associated with discharging the transcriptional co-repressor NuRD, a nucleosome remodeling and the
deacetylase complex, by facilitating histone acetylation in mouse
embryonic fibroblast (MEF) cells [53]. This study supports our
proposed model (Fig. 6) in terms of connecting CARM1-mediated
histone arginine methylation to the dissociation of HDAC activitypossessing transcriptional repressors and augmentation of histone
acetylation.
Although our proposed model has built upon the data obtained from
human adipogenic progenitor cells (hASCs), there are some limitations.

Fig. 6. Epigenetic modification of adipogenesis by EA through the mechanism involved in CARM1 inhibition. A working model illustrating the mechanism by which EA inhibits
adipogenesis in hASCs. (A) Uncommitted hASCs are associated with high levels of HDAC9, a transcriptional co-repressor of adipogenic genes. (B) Upon adipogenic stimuli (including
HF diet and high insulin), CARM1 enzyme facilitates the transfer of two methyl moieties to H3 arginine 17 sites (H3R17me2), which subsequently increases histone acetylation and
HDAC9 dissociation from chromatin. (C) In the presence of EA, EA inhibits CARM1 activity, which blocks subsequent epigenetic modification, resulting in transcription inactivation of
adipogenic genes.
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The primary reason that we used 10 μmol/L of EA (3 μg in 1 ml of
medium) was to mimic our previous in vivo experiment [34]. As we fed
the 0.4% of MGP (18.2-mg EA/g dry extracts) to mice, which provided
~288 μg of EA per day based upon 4 g/day food intake. We also assumed
that 1% of EA may be absorbed in intestinal lumen, and the total blood
volume of mouse would be approximately ~1 ml, which would be
roughly 2.8 μg/ml EA in blood (equivalent to ~10 μmol/L). Secondly,
choosing the lowest end of the EA concentration based on 10–50 μmol/L
range of EA has been routinely used for cellular studies without
cytotoxicity in numerous literature. Unfortunately, EA seems to reach
maximally ~1 μmol/L in serum due to low aqueous solubility and rapid
metabolism by gut microbes [54]. Despite the obvious discrepancy
between in vivo and in vitro study regarding effective EA concentrations,
we believe our study with hASCs would provide mechanistic insights
into EA-mediated epigenetic modification of adiposity in humans,
which is difficult to achieve through in vivo experiment setup. More
research about the optimal EA concentration to exhibit physiological
effectiveness in vivo is warranted. Our current study does not include
information about the metabolites of EA. There is emerging evidence
that urolithin A, EA-derived gut microbial metabolite, exerts various
health benefits [55,56]. We are under investigation whether urolithin A
is also proficient in modulating epigenetic factors that are proposed in
this study. To investigate nutritional significance of EA in vivo, we are
currently conducting animal studies by feeding HF diet with or without
EA supplementation. In addition, to establish the adipose tissue-specific
role of CARM1 on metabolic syndrome, we are under preparation to
generate adipocyte-specific knockout mice of CARM1.
In conclusion, our present study provides mechanism-based evidence
that EA attenuates adipogenesis and offers novel insights into targeting
epigenetic modification for adipogenesis control using a dietary EA.
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